228 related articles for article (PubMed ID: 29064353)
21. Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension.
Iglarz M; Bossu A; Wanner D; Bortolamiol C; Rey M; Hess P; Clozel M
Life Sci; 2014 Nov; 118(2):333-9. PubMed ID: 24582812
[TBL] [Abstract][Full Text] [Related]
22. Vascular Effects of Endothelin Receptor Antagonists Depends on Their Selectivity for ETA Versus ETB Receptors and on the Functionality of Endothelial ETB Receptors.
Iglarz M; Steiner P; Wanner D; Rey M; Hess P; Clozel M
J Cardiovasc Pharmacol; 2015 Oct; 66(4):332-7. PubMed ID: 25992919
[TBL] [Abstract][Full Text] [Related]
23. Regulatory effects of Prohibitin 1 on proliferation and apoptosis of pulmonary arterial smooth muscle cells in monocrotaline-induced PAH rats.
Cao YY; Ba HX; Li Y; Tang SY; Luo ZQ; Li XH
Life Sci; 2020 Jun; 250():117548. PubMed ID: 32173312
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapy of Endothelin-1 Receptor Type A for Pulmonary Arterial Hypertension.
Dai Y; Chen X; Song X; Chen X; Ma W; Lin J; Wu H; Hu X; Zhou Y; Zhang H; Liao Y; Qiu Z; Zhou Z
J Am Coll Cardiol; 2019 May; 73(20):2567-2580. PubMed ID: 31118151
[TBL] [Abstract][Full Text] [Related]
25. [The new endothelin receptor antagonist macitentan: Prospects for therapy of pulmonary arterial hypertension].
Avdeev SN
Ter Arkh; 2016; 88(7):89-97. PubMed ID: 27459621
[TBL] [Abstract][Full Text] [Related]
26. Activation of the right ventricular endothelin (ET) system in the monocrotaline model of pulmonary hypertension: response to chronic ETA receptor blockade.
Jasmin JF; Cernacek P; Dupuis J
Clin Sci (Lond); 2003 Dec; 105(6):647-53. PubMed ID: 12823096
[TBL] [Abstract][Full Text] [Related]
27. [Endothelin: From discovery to pharmacotherapeutic innovations].
Richard V
Presse Med; 2014; 43(7-8):742-55. PubMed ID: 24797866
[TBL] [Abstract][Full Text] [Related]
28. Exploring the failing right ventricle in pulmonary hypertension by cardiac magnetic resonance: An in vivo study utilizing Macitentan.
Murphy G; Jayasekera G; Mullin J; Gallagher L; Welsh DJ
Pulm Circ; 2022 Jul; 12(3):e12124. PubMed ID: 36092794
[TBL] [Abstract][Full Text] [Related]
29. Localization and distribution of endothelin receptor subtypes in pulmonary vasculature of normal and hypoxia-exposed rats.
Soma S; Takahashi H; Muramatsu M; Oka M; Fukuchi Y
Am J Respir Cell Mol Biol; 1999 Apr; 20(4):620-30. PubMed ID: 10100993
[TBL] [Abstract][Full Text] [Related]
30. Selective endothelin ETA and dual ET(A)/ET(B) receptor blockade improve endothelium-dependent vasodilatation in patients with type 2 diabetes and coronary artery disease.
Rafnsson A; Shemyakin A; Pernow J
Life Sci; 2014 Nov; 118(2):435-9. PubMed ID: 24607773
[TBL] [Abstract][Full Text] [Related]
31. Endothelin ET
Vercauteren M; Trensz F; Pasquali A; Cattaneo C; Strasser DS; Hess P; Iglarz M; Clozel M
J Pharmacol Exp Ther; 2017 May; 361(2):322-333. PubMed ID: 28223322
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of Src activation reverses pulmonary vascular remodeling in experimental pulmonary arterial hypertension via Akt/mTOR/HIF-1 signaling pathway.
Liu P; Gu Y; Luo J; Ye P; Zheng Y; Yu W; Chen S
Exp Cell Res; 2019 Jul; 380(1):36-46. PubMed ID: 30802452
[TBL] [Abstract][Full Text] [Related]
33. Endothelin B Receptor Immunodynamics in Pulmonary Arterial Hypertension.
Tabeling C; González Calera CR; Lienau J; Höppner J; Tschernig T; Kershaw O; Gutbier B; Naujoks J; Herbert J; Opitz B; Gruber AD; Hocher B; Suttorp N; Heidecke H; Burmester GR; Riemekasten G; Siegert E; Kuebler WM; Witzenrath M
Front Immunol; 2022; 13():895501. PubMed ID: 35757687
[TBL] [Abstract][Full Text] [Related]
34. microRNA and Pulmonary Hypertension.
Boucherat O; Potus F; Bonnet S
Adv Exp Med Biol; 2015; 888():237-52. PubMed ID: 26663186
[TBL] [Abstract][Full Text] [Related]
35. Role for Runt-related Transcription Factor 2 in Proliferative and Calcified Vascular Lesions in Pulmonary Arterial Hypertension.
Ruffenach G; Chabot S; Tanguay VF; Courboulin A; Boucherat O; Potus F; Meloche J; Pflieger A; Breuils-Bonnet S; Nadeau V; Paradis R; Tremblay E; Girerd B; Hautefort A; Montani D; Fadel E; Dorfmuller P; Humbert M; Perros F; Paulin R; Provencher S; Bonnet S
Am J Respir Crit Care Med; 2016 Nov; 194(10):1273-1285. PubMed ID: 27149112
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.
Sidharta PN; Krähenbühl S; Dingemanse J
Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):437-49. PubMed ID: 25604973
[TBL] [Abstract][Full Text] [Related]
37. Up-regulation of caveolin-1 by DJ-1 attenuates rat pulmonary arterial hypertension by inhibiting TGFβ/Smad signaling pathway.
Gao W; Shao R; Zhang X; Liu D; Liu Y; Fa X
Exp Cell Res; 2017 Dec; 361(1):192-198. PubMed ID: 29069575
[TBL] [Abstract][Full Text] [Related]
38. Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension.
Van der Feen DE; Kurakula K; Tremblay E; Boucherat O; Bossers GPL; Szulcek R; Bourgeois A; Lampron MC; Habbout K; Martineau S; Paulin R; Kulikowski E; Jahagirdar R; Schalij I; Bogaard HJ; Bartelds B; Provencher S; Berger RMF; Bonnet S; Goumans MJ
Am J Respir Crit Care Med; 2019 Oct; 200(7):910-920. PubMed ID: 31042405
[No Abstract] [Full Text] [Related]
39. Downregulation of MicroRNA-126 Contributes to the Failing Right Ventricle in Pulmonary Arterial Hypertension.
Potus F; Ruffenach G; Dahou A; Thebault C; Breuils-Bonnet S; Tremblay È; Nadeau V; Paradis R; Graydon C; Wong R; Johnson I; Paulin R; Lajoie AC; Perron J; Charbonneau E; Joubert P; Pibarot P; Michelakis ED; Provencher S; Bonnet S
Circulation; 2015 Sep; 132(10):932-43. PubMed ID: 26162916
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
